FIGURE 4.

(a) Viability of HUVEC cells treated with different concentration of GNR and GNR‐PEG following incubation for 24 h. (b) Cell viability of HUVEC treated with Liposome, TEX‐Liposome (1/5), TEX‐Liposome (1/20), and TEX‐Liposome (1/100). (c) Viability of 4T1 cells following irradiation of 808 nm NIR laser at 1.00 W/cm² for different time periods. ***p < 0.001 versus free laser. (d) Viability of 4T1 cells treated with PTX, Liposome‐PTX, TEX‐Liposome‐PTX (1/5), TEX‐Liposome‐PTX (1/20), TEX‐Liposome‐PTX (1/100) with different concentration of PTX following incubation for 24 h. **p < 0.01, ***p < 0.001 versus PTX. (e) IC₅₀ values of PTX, Liposome‐PTX, TEX‐Liposome‐PTX (1/5), TEX‐Liposome‐PTX (1/20), and TEX‐Liposome‐PTX (1/100) on 4T1 cells. **p < 0.01 versus PTX. GNR, gold nanorod; HUVEC, human umbilical vein endothelial cell; PTX, paclitaxel; TEX, tumor‐derived exosome